BYSI - BeyondSpring Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
18.49
+1.29 (+7.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close17.20
Open17.37
Bid18.00 x 3100
Ask22.00 x 800
Day's Range17.11 - 18.79
52 Week Range13.06 - 25.79
Volume21,416
Avg. Volume48,570
Market Cap480.078M
Beta (3Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateSep 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Cell Journals Publishes BeyondSpring’s New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation

    NEW YORK, Oct. 08, 2019 -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today.

  • GlobeNewswire

    BeyondSpring Presents Novel Trial Design for DUBLIN-3 Study BPI-2358-103 at ESMO Congress 2019

    NEW YORK, Oct. 01, 2019 -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immune-oncology cancer therapies, today.

  • What Kind Of Shareholders Own BeyondSpring Inc. (NASDAQ:BYSI)?
    Simply Wall St.

    What Kind Of Shareholders Own BeyondSpring Inc. (NASDAQ:BYSI)?

    The big shareholder groups in BeyondSpring Inc. (NASDAQ:BYSI) have power over the company. Institutions often own...

  • GlobeNewswire

    BeyondSpring’s Plinabulin Continues to Build on Superior Product Profile in Breast Cancer Trial for Neutropenia Prevention

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that a Company abstract with findings from BeyondSpring’s Study 106 has been accepted for poster presentation at this year’s European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain. The poster, titled, “The Effect of Increasing Doses of Pegfilgrastim (Peg) on Thrombocytopenia (T) in Breast Cancer (BC) Patients (pts) Receiving Taxotere (Doc), Doxorubicin, Cyclophosphamide (TAC) and Plinabulin (Plin),” will be presented on Sept. 28 in Poster Hall 4. In Study 106, BeyondSpring evaluated the effects of Pegfilgrastim (Neulasta®) combined with Plinabulin on absolute neutrophil counts and platelet count.

  • GlobeNewswire

    BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results

    - To Submit New Drug Applications (“NDAs”) in China for Both Non-Small Cell Lung Cancer (“NSCLC”) and Chemotherapy-Induced Neutropenia (“CIN”) in Q1 2020 - - To Submit.

  • ACCESSWIRE

    BeyondSpring, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / September 18, 2019 / BeyondSpring, Inc. (NASDAQ: BYSI ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on September 18, 2019 at 8:00 ...

  • GlobeNewswire

    BeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019

    BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report second-quarter 2019 financial results and host an operational and clinical update conference call on Wednesday, September 18, 2019, at 8:00 a.m. Eastern Time. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).

  • GlobeNewswire

    BeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company’s novel design for Study 103 was selected for poster presentation at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Barcelona, Spain. The poster, titled “DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P) / Docetaxel (D) Combination with D Alone in Stage IIIB / IV NSCLC,” was presented on September 9 from 10:15 a.m.-6:15 p.m. local time. Study 103, a Phase 3 global multi-center clinical trial, was undertaken in stage IIIB/IV, EGFR-wild type non-small cell lung cancer (NSCLC) patients [n=554], in 2nd and 3rd line therapy with Docetaxel plus Plinabulin, or Docetaxel in a 1:1 ratio.

  • GlobeNewswire

    BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference in New York, NY on Tuesday, September 10, 2019, at 10:00 a.m. Eastern Time. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).

  • GlobeNewswire

    BeyondSpring’s Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the results of its head-to-head clinical trial for Study BPI-2358-105, accepted as an abstract titled, “Quality of Life (QoL) in Advanced NSCLC Patients Treated with Docetaxel and with Either Plinabulin or Pegfilgrastim for the Prevention of Neutropenia.” The poster (Abstract No. 2513) will be presented during the IASLC World Conference on Lung Cancer in Barcelona, Spain on September 8, 2019 from 9:45 a.m. - 6:00 p.m. local time.

  • GlobeNewswire

    BeyondSpring Announces Pricing of Public Offering of Ordinary Shares

    BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 2,058,825 ordinary shares at a public offering price of $17.00 per share. The offering was led by Decheng Capital. The gross proceeds from the public offering are expected to be $35.0 million, before deducting underwriting discounts and commissions and other offering expenses.

  • GlobeNewswire

    BeyondSpring Announces Proposed Public Offering of Ordinary Shares

    BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced that it plans to launch an underwritten public offering of its ordinary shares. The offering is being led by Decheng Capital LLC. The Company also expects to grant the underwriter an option to purchase up to an additional 15% of the ordinary shares being offered to cover over-allotments. The Company intends to use the net proceeds of this offering to support continued clinical and pre-clinical development and for general corporate purposes.

  • GlobeNewswire

    BeyondSpring Provides Operational Update and First Quarter 2019 Financial Results

    - New and Compelling Plinabulin Data Presented at Key Scientific Conferences - - To Submit New Drug Applications (NDAs) in China for Both Non-Small Cell Lung Cancer (NSCLC) and.

  • Benzinga

    18 Stocks Joining The Russell Indices

    The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...

  • GlobeNewswire

    BeyondSpring Set to Join FTSE Russell 3000® Index

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that it will join the FTSE Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the U.S. market opens on July 1, 2019, according to a preliminary list of additions posted June 7, 2019. Membership in the Russell 3000® Index, which remains in place for one year, means the automatic inclusion of BeyondSpring common stock in index funds designed to track stocks included in the Russell 3000® Index. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

  • GlobeNewswire

    BeyondSpring to Present at the Jefferies 2019 Healthcare Conference

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the Jefferies 2019 Healthcare Conference in New York, NY on Friday, June 7, 2019, at 9:00 a.m. Eastern Time. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).

  • GlobeNewswire

    BeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention Presented at ISPOR 2019

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company’s abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 2019 Conference. ISPOR is internationally recognized as the leading educational and scientific organization for health economics and outcomes research (HEOR) and its use in healthcare decisions. The data, derived from BeyondSpring’s Phase 2 Study 105, shows that Plinabulin at 20mg/m2 has a similar efficacy profile in reducing docetaxel-induced neutropenia as Neulasta 6mg (pegfilgrastim, the current standard of care), with the added safety benefit of avoiding the patient-reported bone pain that’s typically observed with Neulasta.

  • GlobeNewswire

    BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that two of the Company’s abstracts on its lead asset, Plinabulin, have been accepted for publication in the Proceedings of this year’s ASCO Annual Meeting. The data, derived from BeyondSpring’s Phase 2 Study 106, provides a strong rationale for the Plinabulin Neulasta (pegfilgrastim) combination for the prevention of chemotherapy-induced neutropenia (CIN) for improved CIN control.

  • GlobeNewswire

    BeyondSpring Files 2018 Annual Report on Form 20-F

    NEW YORK, April 30, 2019 -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that.

  • BeyondSpring Inc. (BYSI) Q4 2018 Earnings Call Transcript
    Motley Fool

    BeyondSpring Inc. (BYSI) Q4 2018 Earnings Call Transcript

    BYSI earnings call for the period ending December 31, 2018.

  • GlobeNewswire

    BeyondSpring Provides Business Update and Fourth Quarter and Full-Year 2018 Financial Results

    - Significant Clinical Data Generated for Plinabulin - - On Track to Submit New Drug Applications (NDAs) for Plinabulin to China’s National Medical Products Administration.

  • GlobeNewswire

    BeyondSpring to Host Fourth-Quarter and Full-Year 2018 Financial Results and Operational Update Conference Call on April 30, 2019

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2018 financial results and host an operational and clinical update conference call on Tuesday, April 30, 2019, at 8:00 a.m. Eastern Time. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).

  • GlobeNewswire

    BeyondSpring to Present at the 18th Annual Needham Healthcare Conference

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 8:00 a.m. Eastern Time at the Westin Grand Central Hotel in New York, NY. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).

  • GlobeNewswire

    BeyondSpring’s Lead Asset, Plinabulin, Shifts the Balance of Macrophages Towards Anti-Cancer M1s

    BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present a promising new strategy for cancer treatment involving the ability of lead asset, Plinabulin, to positively shift the balance of macrophage phenotypes for beneficial anti-cancer effect at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia. The results will be highlighted in a poster presentation titled, “Microtubule Destabilization by Plinabulin Generates Anti-Tumor Immune Response through Repolarization of Intratumoral Macrophages,” taking place on April 3rd from 8 a.m. to 12 p.m. local time.